Seres Banks Serious Cash To Drive Microbiome Therapy To Market

Nestlé Health Science Bags US Rights To SER-109 for CDI

Seres and rival Ferring are both hoping to have the first-ever FDA-approved microbiome therapeutic but the US firm has secured a strong commercial partner in Nestlé's Aimmune pharma arm to drive SER-109 over the finishing line.

Race
Rivals lining up in race for first microbiome therapy approval • Source: Shutterstock

The race is on to be the first company to have a microbiome therapy approved, with US firm Seres Therapeutics, Inc. staking its claim after inking a lucrative deal with Nestle Health Science to jointly commercialize SER-109 in North America for recurrent Clostridioides difficile infection (CDI).

The partners started collaborating back in January 2016 when Nestlé, which had already bought a stake in the Cambridge, MA-based...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category